Skip to main content
. 2005 Aug 7;11(29):4484–4489. doi: 10.3748/wjg.v11.i29.4484

Table 5.

Adverse events possibly or probably related to study treatment, occurring with a frequency higher than 5%

r-hIFN β-1a (n = 24, %) r-hIFN β-1a + ribavirin (n = 35, %)
Fatigue 4 (16.7) 4 (11.4)
Pyrexia 2 (8.3) 6 (17.1)
Anemia 0 (0.0) 6 (17.1)
Erythema 4 (16.7) 2 (5.7)
Headache 4 (16.7) 0 (0.0)
Thrombocytopenia 3 (12.5) 0 (0.0)
Neutropenia 0 (0.0) 2 (5.7)
Depression 2 (8.3) 0 (0.0)
Insomnia 0 (0.0) 2 (5.7)
Weight loss 0 (0.0) 2 (5.7)